Shivalik Rasayan Ltd (SHIVALIK) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Shivalik Rasayan Ltd on NSE and BSE, with an AI summary of each filing.
Announcement as per Regulation 30 of SEBI LODR Regulation 2015
Others (Uncategorized) · 03 Nov 2026, 7:25 pm
Shivalik Rasayan Files USFDA Drug Master File for Avapritinib API Shivalik Rasayan Limited has successfully filed a Drug Master File (DMF) with the USFDA for Avapritinib API, with the Complete Assessment already concluded. Avapritinib is indicated for the treatment of Gastrointestinal Stromal Tumors (GIST). The innovator product, marketed by Sanofi under the brand name Ayvakit, generated global revenues of USD 700 million during CY25. This regulatory milestone positions the company to target a commercially significant oncology market opportunity in the United States.
Voting Results along with Scrutinizer''s Report for the 48th Annual General Meeting held on 28.09.2026
Annual General Meeting · 29 Sept 2026, 9:15 pm
Disclosure pursuant to Regulation 29(1) of SEBI SAST Regulations, 2011
Others (Uncategorized) · 29 Sept 2026, 6:01 pm
Ginnerup Capital Acquires Convertible Warrants in Shivalik Rasayan via Preferential Allotment Ginnerup Capital ApS acquired 3,99,990 fully convertible warrants of Shivalik Rasayan Limited on 14th Sep'26 via preferential allotment, representing 2.36% of the company's total diluted paid-up share capital. Prior to the transaction, Ginnerup Capital held 5,06,550 equity shares (3.22% of pre-issue voting capital). Post-allotment, the entity's aggregate holding stands at 9,06,540 shares and warrants, representing 3.16% of total voting capital and 5.34% of the total diluted share capital (1,69,80,355 equity shares).
Proceedings of 48th Annual General Meeting of the Company held on 28.09.2026
Annual General Meeting · 28 Sept 2026, 8:24 pm
Shivalik Rasayan Limited has informed the Exchange regarding Outcome of Board Meeting held on September 14, 2026.
Outcome · 14 Sept 2026, 9:51 pm
Shivalik Rasayan Approves Preferential Allotment of Shares and Convertible Warrants Shivalik Rasayan’s board approved the preferential allotment of 2.82 lakh equity shares (face value Rs. 5) at Rs. 250 per share to public investors, raising Rs. 7.05 cr on 14th Sep'26. Post-allotment, paid-up capital increased to Rs. 8.02 cr (1.60 cr shares). The board also approved allotting 9.48 lakh fully convertible warrants at Rs. 250 each to promoter and public categories, raising Rs. 23.70 cr. On a fully diluted basis, paid-up equity share capital will expand to Rs. 8.49 cr comprising 1.70 cr equity shares.
Outcome of meeting of the Board of Directors for the Allotment of 2,82,000 Equity Shares and 9,47,990 Fully Convertible Warrants ('Warrants') at an issue price of Rs. 250/- each
Others (Uncategorized) · 14 Sept 2026, 9:46 pm
Shivalik Rasayan Approves Preferential Allotment of Shares and Convertible Warrants Shivalik Rasayan's board approved the preferential allotment of 2.82 lakh equity shares at Rs. 250 each to public investors, raising Rs. 7.05 cr on 14th Sep'26. Consequently, paid-up equity capital increased to Rs. 8.02 cr across 1.60 cr shares. The board also approved allotting 9.48 lakh fully convertible warrants at Rs. 250 each for Rs. 23.70 cr to promoter and public entities. Upon full warrant conversion, the company's fully diluted paid-up equity capital will reach Rs. 8.49 cr, comprising 1.70 cr shares of Rs. 5 face value.
Annual Report for the Financial year 2025-26
Others (Uncategorized) · 04 Sept 2026, 12:09 am
Intimation of Annual General Meeting to be held on 28.09.2026
Annual General Meeting · 04 Sept 2026, 12:05 am
Revised proceedings of EGM held on 20.08.2026
Extra Ordinary General Meeting · 25 Aug 2026, 4:40 pm
Shivalik Rasayan EGM Approves Preferential Allotment of Shares and Warrants Shivalik Rasayan held an EGM on 20-Aug'26 to approve two key resolutions. The first was the issuance of up to 372,000 equity shares to the "Public" category on a preferential basis. The second was the issuance of up to 9,48,000 fully convertible warrants to the "Promoter and Promoter Group" and "Public" category, also on a preferential basis. The company cited severe weather and network disruptions in Dehradun for a delay in submitting the EGM proceedings to the exchanges. Voting results will be disclosed separately.
Intimation as per Regulation 7(3) of the SEBI PIT Regulations, 2015
Others (Uncategorized) · 24 Aug 2026, 5:58 pm
Shivalik Rasayan: Former Director Disposes 25,000 Shares Former Director Sanjay Bansal, a connected person, sold 25,000 equity shares of Shivalik Rasayan on the open market. The transaction, valued at ₹68.31 lakh, occurred on 21-Aug'26. This sale reduced his holding from 50,000 shares (0.32% stake) to 25,000 shares (0.16% stake). The company reported this insider transaction to the exchanges on 24-Aug'26. The disposal was executed on both the NSE and BSE.
Revised Voting Results & Scrutinizer''s Report for the Extra-Ordinary General Meeting held on 20.08.2026
Extra Ordinary General Meeting · 22 Aug 2026, 5:15 pm
Shivalik Rasayan EGM Approves Equity & Warrant Issuance Shivalik Rasayan announced shareholders approved two special resolutions at its EGM on 20 Aug'26. Both resolutions passed with overwhelming support of over 99.99%. Resolution 1 approved the preferential issuance of up to 372,000 equity shares to public category investors. Resolution 2 approved the preferential issuance of up to 948,000 fully convertible warrants to both promoter and public category entities. Overall voter turnout from total shareholding was 56.17%. The resolutions pave the way for potential capital raising and equity dilution.
Voting Results of Extra-Ordinary General Meeting held on 20.08.2026
Extra Ordinary General Meeting · 22 Aug 2026, 3:48 pm
Shivalik Rasayan EGM Approves Preferential Allotment of Shares and Warrants Shareholders approved two key special resolutions at the EGM on 20-Aug-26. The first resolution, passed with 99.9989% approval, was for the issuance of up to 372,000 equity shares to public category investors on a preferential basis. The second resolution, passed with 99.9998% approval, authorized the issuance of up to 948,000 fully convertible warrants to both promoter and public category investors. Both resolutions received overwhelming support, paving the way for capital raising and potential equity dilution.
Proceedings of Extra-Ordinary General Meeting of the Company held on 20.08.2026 at Hotel Saffron Leaf GMS Road Dehradun
Extra Ordinary General Meeting · 21 Aug 2026, 5:15 pm
Shivalik Rasayan Seeks Approval for Preferential Allotment of Equity and Warrants Shivalik Rasayan held its EGM on 20th Aug'26 to consider two special resolutions for preferential capital raising. The first resolution proposed the issuance of up to 372,000 equity shares to the "Public" category. The second sought approval for issuing up to 9,480,000 fully convertible warrants to both the "Promoter and Promoter Group" and "Public" categories. The remote e-voting window was open from 17th Aug'26 to 19th Aug'26. Final consolidated voting results will be disclosed separately upon receipt of the scrutinizer's report.
Fixes record date for the AGM and Final Dividend for the financial year ended on 31.03.2026
Dividend · 14 Aug 2026, 10:47 pm
Submission of BRSR report for the financial year ended on 31.03.2026
Others (Uncategorized) · 14 Aug 2026, 10:45 pm
Shivalik Rasayan FY26 BRSR Highlights Business Mix and Pending Litigation Shivalik Rasayan's FY26 standalone BRSR reveals Agrochemicals dominate turnover at 88.85%, with Pharma API (5.31%) and R&D (5.83%) making smaller contributions. Exports constitute only 1.39% of total turnover, with the rest domestic. Related party transactions include sales of ₹1345.40 lakhs and investments of ₹8,109.13 lakhs. A key contingent liability is a pending litigation for an alleged excess input tax credit of ₹1.18 crore from FY18, which the company is contesting at the Nainital High Court. The company has a 47.37% holding in Growel Remedies.
Wee wish to inform that the Board of Directors in its meeting held today approved the un-audited financial results for the quarter ended on 30.06.2026
Financial Result · 14 Aug 2026, 10:37 pm
Shivalik Rasayan Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve un-audited financial results ....
Intimation · 14 Aug 2026, 5:30 am
Shivalik Rasayan Board Meeting on Aug 14, 2026 for Q1 Results Shivalik Rasayan has scheduled a Board of Directors meeting on 14 Aug'26 to consider and approve its un-audited standalone and consolidated financial results for the quarter ended 30 Jun'26. The Board will also consider and approve the draft Annual Report for FY26. In accordance with SEBI regulations, the trading window for company securities has been closed since 01 Jul'26 and will reopen 48 hours after the financial results are publicly declared.
Intimation as per Regulation 7(3) of PIT Regulations, 2015
Others (Uncategorized) · 05 Aug 2026, 9:07 pm
Shivalik Rasayan: Former Director Sells 50,000 Equity Shares Sanjay Bansal, a former Director and connected person of Shivalik Rasayan, sold 50,000 equity shares in an open market transaction on NSE & BSE. The sale, valued at ₹124.87 million, occurred between 03-Aug-26 and 05-Aug-26. This disposal reduces his shareholding from 100,000 shares (0.63% stake) to 50,000 shares (0.32% stake). The company was formally intimated of the transaction on 05-Aug-26, as per SEBI's insider trading regulations.
Intimation as per Regulation 7(3) of PIT Regulations, 2015
Others (Uncategorized) · 28 Jul 2026, 9:36 pm
Shivalik Rasayan: Former Director Sells 60,000 Shares Sanjay Bansal, a former director of Shivalik Rasayan Limited, sold 60,000 equity shares via an on-market transaction for a total value of Rs. 1,54,55,262. The transaction occurred between 24-Jul'26 and 28-Jul'26. Following the sale, Bansal's shareholding in the company decreased from 1,60,000 shares (1.01% stake) to 1,00,000 shares (0.63% stake). The company reported this transaction to the exchanges on 28-Jul'26 as per SEBI insider trading regulations.
Notice of calling Extra-Ordinary General meeting to be held on Thursday, August 20, 2026
Extra Ordinary General Meeting · 27 Jul 2026, 11:38 pm
Shivalik Rasayan To Raise ₹33 Crore Via Preferential Issue of Shares and Warrants Shivalik Rasayan announced an EGM on 20 Aug'26 to approve a preferential issue to raise up to ₹33 Cr. The company plans to issue up to 372,000 equity shares to public investors and up to 948,000 fully convertible warrants to promoter and public entities, both priced at ₹250 per security. Warrants are convertible within 18 months. Proceeds will fund R&D activities (₹18 Cr), capex (₹7 Cr), and general corporate purposes (₹8 Cr). The issue price represents a premium over the ₹248.76 floor price.
Revised outcome
Revision of outcome · 24 Jul 2026, 3:34 pm
Shivalik Rasayan Board Approves Capital Raise of ₹33 Crore via Preferential Allotment Shivalik Rasayan's board, on 23 Jul'26, approved a preferential issue to raise up to ₹33 Cr. This includes issuing 3.72 lakh equity shares at ₹250/share, aggregating ₹9.30 Cr, to public investors. Additionally, 9.48 lakh convertible warrants will be issued at ₹250/warrant, totaling ₹23.70 Cr, to promoter and public entities including Growel Remedies. Warrants are convertible into equity shares within 18 months. The company scheduled an Extra-Ordinary General Meeting for 20 Aug'26 to seek shareholder approval for these proposals.
Issue & Allotment of up to 3,72,000 Equity Shares & 9,48,000 Fully Convertible Warrants ('Warrants') at an issue price of Rs. 250/-
Outcome · 23 Jul 2026, 11:23 pm
Shivalik Rasayan Board Approves Preferential Issues to Raise ₹33 Crore On 23 Jul'26, Shivalik Rasayan's board approved raising ₹33 Cr via preferential issues. This includes issuing 3.72 lakh equity shares to public investors for ₹9.3 Cr, and 9.48 lakh convertible warrants to promoter and public entities for ₹23.7 Cr. Both shares and warrants are priced at ₹250 each. Warrants are convertible into equity within 18 months. The company also approved an Extra-Ordinary General Meeting (EGM) on 20 Aug'26 to seek shareholder approval for these proposals.
Shivalik Rasayan Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve Issuance of Equity shares/warrants ....
Intimation · 23 Jul 2026, 5:30 am
Shivalik Rasayan Board to Consider Capital Raise on Jul 23 Shivalik Rasayan's Board of Directors will meet on 23 Jul'26 to consider and approve a proposal for a capital raise. The company is evaluating various fundraising instruments, including equity shares and convertible securities. Potential routes for the issuance include a Preferential Issue, Rights Issue, or Qualified Institutional Placement (QIP). The meeting will also determine the pricing and other modalities of the potential issue. The trading window for insiders remains closed until 48 hours after the board meeting concludes.
intimation as per regulation 7(3) of the SEBI PIT Regulations, 2015
Others (Uncategorized) · 04 Jun 2026, 6:20 pm
Shivalik Rasayan: Former Director Sells 40,000 Equity Shares Shivalik Rasayan disclosed that former Director Sanjay Bansal, a connected person, sold 40,000 equity shares in an open market transaction on the NSE. The sale, valued at ₹1.02 crore, was executed between 02-Jun'26 and 03-Jun'26. Following the disposal, Mr. Bansal's shareholding in the company decreased from 200,000 shares (1.27% stake) to 160,000 shares (1.01% stake). The company was intimated of this transaction on 03-Jun'26.
We wish to inform you that the Board of Directors of the Company approved the financial results for the quarter and year ended on 31.03.2026
Financial Result · 27 May 2026, 10:41 pm
Shivalik Rasayan Q4FY26 Results, Dividend, and Board Changes Announced Shivalik Rasayan's board approved Q4 & FY26 results on 27 May'26 and declared a final dividend of ₹0.50 per share (10%) for FY26. Consolidated Q4FY26 net profit was ₹717.32 lakhs vs ₹519.06 lakhs YoY, with revenue at ₹10,281.57 lakhs vs ₹6,939.46 lakhs YoY. For FY26, consolidated net profit stood at ₹1,796.88 lakhs, a decrease from ₹2,042.26 lakhs YoY. The board also noted the resignation of Non-Executive Director Mr. Sanjay Bansal and appointed new Internal and Cost Auditors for FY27.